-
Recent Posts
- Dementia-Friendly Communities Provision, Viewed as a Social Determinant of Health (JGCR / NHS England / WHO)
- International Perspectives on the Possible Impact of the COVID-19 Pandemic and Lockdown on Abuse of the Elderly (JGCR / American Journal of Geriatric Psychiatry / JAGS)
- Updates Relating to the Lancet Commission on Dementia Prevention, Intervention, and Care (Lancet / Alzheimer’s Research and Therapy / Alzheimer’s and Dementia)
- A Brief Review of How the COVID-19 Pandemic Relates to Elderly Care and Research (JGCR)
- Some Speculated / Potential Benefits of COVID-19 (JGCR / BBC Radio 4’s Rethink / BGS)
Archives
- September 2020
- August 2020
- June 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
Categories
- Antipsychotics
- Assistive Technology
- Charitable Bodies
- Commissioning
- Delirium
- Depression
- Enhancing the Healing Environment
- Falls
- Falls Prevention
- Guidelines
- Hip Fractures
- Housing
- Hypertension
- In the News
- Integrated Care
- International
- Local Interest
- Mental Health
- Models of Dementia Care
- National
- ADASS
- All-Party Parliamentary Group (APPG) on Dementia
- BSI
- CQC: Care Quality Commission
- Department of Health
- Department of Health and Social Care (DHSC)
- Health Education England (HEE)
- Housing LIN
- MAGDR
- Mental Health Foundation
- Mental Health Network (NHS Confederation)
- MHP Health Mandate
- National Audit Office
- National Voices
- NEoLCIN
- NEoLCP
- NHS
- NHS Alliance
- NHS Confederation
- NHS Employers
- NHS England
- NHS Evidence
- NHS Improvement
- NICE Guidelines
- NIHR
- NIHRSDO
- Northern Ireland
- Patients Association
- Public Health England
- RCN
- Royal College of Physicians
- Royal College of Psychiatrists
- SCIE
- Scotland
- UK
- UK NSC
- Wales
- Non-Pharmacological Treatments
- Nutrition
- Pain
- Parkinson's Disease
- Patient Care Pathway
- Person-Centred Care
- Personalisation
- Pharmacological Treatments
- Proposed for Next Newsletter
- Quick Insights
- Standards
- Statistics
- Stroke
- Systematic Reviews
- Telecare
- Telehealth
- Universal Interest
Google Translate (100+ Languages)
Tag Archives: Drug Discovery Programmes
A Further Set-Back for Progress in Dementia Drug Development? (BBC News)
Summary Drug company Pfizer is to cease activity in its neuroscience drug discovery programmes, which will impact on ongoing research into drugs for Alzheimer’s Disease and Parkinson’s Disease. Paradoxically the company does promise plans to create a new fund dedicated … Continue reading →
Posted in BBC News, For Researchers (mostly), In the News, International, Management of Condition, Pharmacological Treatments, Quick Insights, Universal Interest
|
Tagged Big Pharma, Dementia Research, Dementia Research Funding, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Drug Discovery Programmes, Drug Identification, Drug Trials Failure Rate, Drug-Development Pipeline, Global Context, Global Outlook, International Organisations, International Programmes, Neurological Conditions, Neurological Disease, Neurological Disorders, Neuroscience Drug Discovery Programmes (Pfizer), Neuroscience Research, Pfizer, Pfizer Inc., Pharmaceutical Industry, Research and Development, Research and Innovation, Research Commitment, Research Funding
|
Leave a comment
Research Towards a World Without Dementia: Marking World Alzheimer’s Day / World Alzheimer’s Month 2017 (Alzheimer’s Disease International / Department of Health)
Summary Information is available from Alzheimer’s Disease International (ADI) concerning World Alzheimer’s Month (September) and World Alzheimer’s Day 2017, which was on September 21st 2017. The theme for this year’s World Alzheimer’s Month campaign is again “Remember Me”. The UK … Continue reading →
Posted in Charitable Bodies, Commissioning, Department of Health, Diagnosis, In the News, Integrated Care, International, Management of Condition, Mental Health, Models of Dementia Care, National, NHS, Non-Pharmacological Treatments, Person-Centred Care, Pharmacological Treatments, Quick Insights, Standards, UK, Universal Interest
|
Tagged 70th World Health Assembly Adopted Global Action Plan on Dementia, Ageing Population, Awareness, Awareness Campaigns, Awareness Raising, Carey Mulligan, Carey Mulligan: UK Global Dementia Friends Ambassador, Collaborative Research, Collaborative Working, Community and Voluntary Sector, Dementia Awareness Campaigns, Dementia Awareness Raising, Dementia Friends, Dementia Friends Programme, Dementia Research, Dementia Research Institute (DRI), Dementia-Friendly Communities, Dementia-Friendly Environments, Dementia-Friendly Organisations, Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Drug Discovery Programmes, First G8 Dementia Summit, Former Health Secretary Jeremy Hunt, G8 Dementia Summit, G8 Dementia Summit Declaration, G8 Dementia Summit: Global Action Against Dementia, Global Action Against Dementia, Global Action Plan on Dementia, Global Alzheimer’s and Dementia Action Alliance, Global Alzheimer’s and Dementia Action Alliance (GADAA), Global Context, Global Dementia Friends Ambassadors, Global Leadership, International Collaborations, International Dementia Research, Leadership for Compassionate Care, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, Partnership Working, Reducing Stigma, Research and Development, Research and Innovation, Research Commitment, Rt Hon Jeremy Hunt MP: Former Secretary of State for Health, Stigma of Dementia, Stigma-Free Environments, UK Dementia Research Institute, UK Dementia Research Institute (UK DRI), Voluntary Organisations, WHO Global Action Plan on the Public Health Response to Dementia 2017-2025, World Alzheimer's Month 2017 (Remember Me), World Alzheimer’s Day 2017, World Alzheimer’s Month 2017, Yuichiro Miura: Japan’s Dementia Supporters Ambassador
|
Leave a comment
Grounds for Cautious Optimism Regarding Two Drugs Re-Purposed for Neurodegenerative Diseases? (BBC News / MRC / NHS Choices / Brain)
Summary Animal research, involving mice, has indicated promising results for the potential of two re-purposed drugs in helping to slow or halt the progression of a number of neurodegenerative brain diseases, including dementia. “The best known drug of the pair … Continue reading →
Posted in Animal Studies, BBC News, For Researchers (mostly), In the News, National, NHS Digital (Previously NHS Choices), Parkinson's Disease, Pharmacological Treatments, Quick Insights, UK, Universal Interest
|
Tagged Abnormal Prion Protein, Alzheimer's Disease, Alzheimer's Research UK, Alzheimer’s Drug Discovery Foundation, Alzheimer’s Research UK (ARUK), Alzheimer’s Research UK Drug Discovery Institute, Amyloid Beta, Amyloid Beta Protein, Amyloid Proteins, Amyloid-β (Aβ), Amyloid-β (Aβ) Accumulation, Autoimmune Attacks, Autoimmune Cell Defences, BBC Health News, Behind the Headlines, Brain (Journal), Centre for Analytical Bioscience: University of Nottingham, CJD, Creutzfeldt-Jakob Disease, Creuzfeldt Jacob Disease (CJD), Department of Clinical Neurosciences: University of Cambridge, Dibenzoylmethane, Dibenzoylmethane (DBM): Potential Anti-Cancer Drug, Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Dr David Dexter: Parkinson's UK, Dr Doug Brown: Director of Research and Development at Alzheimer's Society, Drug Discovery Programmes, eIF2a-P-Mediated Translational Repression (Pathway of Neurodegeneration), Frontotemporal Dementia (FTD), Huntingtin Protein, Huntington’s Disease, α-Synuclein, α-Synuclein Aggregation, Lentivirally Mediated RNA Interference (RNAi), Medical Research Council (MRC), Medical Research Council (UK), Medical Research Council Toxicology Unit: University of Leicester, Medical Research Council’s (MRC) Toxicology Unit, Microscopic Worms, Misfolded Prion Protein (PrP), Misfolded Proteins, Motor Neurone Disease (MND), MRC Toxicology Unit: University of Leicester, MRC: Medical Research Council, Multiple Sclerosis, National Institute for Neurological Disorders and Stroke, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neuronal Loss, Neuroprotection, Parkinson's, Potential Repurposing of Drugs to Slow Progression of Alzheimer’s Disease, Prion Diseases, Prion Protein (PrP(C)), Prion-Infected Mice, Prof. Giovanna Mallucci, Professor Giovanna Mallucci: Associate Drector of UK Dementia Research Institute, Protein Misfolding, Rare Prion Diseases, Repurposing of Drugs, Synucleinopathy, Tau, Tau Protein, Tauopathy, Translational Research, Transmissible Spongiform Encephalopathies, Trazodone, Trazodone Hydrochloride (Antidepressant), UK Dementia Research Institute, UK Dementia Research Institute (UK DRI), Unfolded Protein Response (UPR), University of Cambridge, University of Leicester, University of Nottingham, Worms: C. elegans
|
Leave a comment
Future Director of the UK Dementia Research Institute (MRC / Guardian / JAMA Neurology)
Summary Professor Bart De Strooper has been appointed as the Director of the UK Dementia Research Institute (UK DRI). Prof. De Strooper currently leads the Laboratory for the Research of Neurodegenerative Diseases at the University of Leuven and is scientific … Continue reading →
Posted in For Researchers (mostly), In the News, International, Models of Dementia Care, National, Quick Insights, UK, Universal Interest
|
Tagged Ageing Population, Belgium, Biomarker Development, Biomarkers, Biomarkers Research Programmes, Brain Imaging, Dementia and Alzheimer's Disease: Leading Cause of Death in 2015, Dementia Challenge 2020, Dementia Research, Dementia Research Careers, Dementia Research Institute (DRI), Dementia Research: Roadmap for the Next Decade, Department of Neuroscience: Mayo Clinic Florida, Diagnostic Imaging, Diagnostics, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Drug Discovery Programmes, Environmental Risk Factors, Epidemiology, G8 Dementia Summit Declaration, Genetics, Global Action Against Dementia, Global Context, Global Leadership, Guardian, Guardian (Newspaper), International Dementia Research, International Dementia Research Inventories, JAMA Neurology, Jo Johnson: Universities and Science Minister, Johns Hopkins University, Laboratory for the Research of Neurodegenerative Diseases: University of Leuven, Laboratory of Neurogenetics: National Institute on Aging, Lifestyle Risk Factors, Mayo Clinic Florida, Medical Research Council (MRC), Medical Research Council (UK), Michael Arthur: UCL President and Provost Professor, MRC: Medical Research Council, National Institutes of Health (NIH), National Institutes of Health (US), National Institutes of Health / National Institutes on Aging, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, Neuroimaging of Dementia, Neurology, Neuromuscular Diseases Research Section: National Institute on Aging, Neuroscience, Overlapping Risk Factors, Potential Drug Targets, Preclinical Biomarkers and Dementia, Professor Bart De Strooper: Director of the UK Dementia Research Institute (UK DRI), Recruitment of Research Leaders / Rising Stars, Research and Development, Research and Innovation, Research Commitment, Sir John Savill: Chief Executive of the Medical Research Council, UCL DRI Hub, UK Dementia Research Institute, UK Dementia Research Institute (UK DRI), United States, University College London (UCL), University of Leuven, US National Institutes of Health, US National Institutes of Health (NIH), USA, VIB (Belgium), VIB-K.U.Leuven
|
Leave a comment
Earlier Diagnosis of Parkinson’s Disease? (BBC News / Acta Neuropathologica Communications)
Summary Recent animal research, using rats, suggests there may be a cheap and non-invasive method of detecting Parkinson’s Disease early – before symptoms develop – by identifying changes in the eye. The same study also offers early evidence for a … Continue reading →
Posted in Animal Studies, BBC News, Diagnosis, For Doctors (mostly), For Researchers (mostly), In the News, Parkinson's Disease, Pharmacological Treatments, Quick Insights, UK
|
Tagged Acta Neuropathologica Communications, BBC Health News, Belgium, Biomarkers, DARC: Detection of Apoptosing Retinal Cells, Department of Biology: University of Leuven, Department of Surgery and Cancer: Imperial College London, Drug Discovery Programmes, Early Diagnosis, Early Diagnosis of Parkinson’s Disease, Eye Test to Detect Parkinson's Disease, Faculty of Medicine: Imperial College London, HEYEX® Thickness Map Analysis (Heidelberg Engineering), Imperial College Healthcare NHS Trust, Imperial College London, Imperial College Ophthalmology Research Group (ICORG): Imperial College London, Liposomal Formulation of PPAR-γ (Peroxisome Proliferator-Activated Receptor Gamma) Agonist Rosiglitazone, Liposome-Encapsulated Rosiglitazone, Loss of Dopaminergic Neurons in pars compacta of Substantia Nigra (SNpc), Neural Circuit Development and Regeneration Research Group: University of Leuven, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, Neuroprotective Agents, Neuroprotective Effect of Rosiglitazone, Nigrostriatal Neurons, Non-Invasive Biomarkers, Ocular Manifestations in Neurodegenerative Diseases, Parkinson’s UK, Preclinical Biomarkers in Parkinson's Disease, Rats, Retina as Early Biomarker of Neurodegeneration, Retinal Assessments Using DARC (Detection of Apoptosing Retinal Cells), Retinal Biomarkers, Retinal Changes as Surrogate Biomarker for Parkinson's Disease, Retinal Ganglion Cells (RGCs), Retinal Manifestations of Parkinson's Disease, Retinal Thickness, Rosiglitazone, Rotenone-Induced Model of Parkinson's Disease, School of Pharmacy: University of London, Substantia Nigra, Surrogate Biomarkers of Neurodegeneration, UCL Institute of Ophthalmology: University College London, University College London (UCL), University of Leuven, Western Eye Hospital: Imperial College Healthcare NHS Trust
|
Leave a comment
Faintest Hints of Promise From a Recent Dementia Drug Trial? (BBC News / Alzheimer’s Association International Conference)
Summary Data from a recent trial involving 891 patients, presented at the Alzheimer’s Association International Conference in Toronto this week, indicates that an experimental new drug (LMTX) appears to slow the death of brain cells and preserve mental function in … Continue reading →
Posted in Alzheimer’s Disease International (ADI), BBC News, Charitable Bodies, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Management of Condition, Models of Dementia Care, Pharmacological Treatments, Quick Insights, Universal Interest
|
Tagged Abnormal Proteins (Tau), Alzheimer Disease and Related Disorders Research Unit of the McGill University Research Centre for Studies in Aging (Douglas Mental Health University Institute), Alzheimer's Disease Research Unit: McGill University (Canada), Alzheimer’s Association, Alzheimer’s Association International Conference® (AAIC®) 2016, BBC Health News, Degenerative Tauopathy, Dementia Research, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Douglas Mental Health University Institute: McGill University Research Centre for Studies in Aging, Dr Serge Gauthier: Director of Alzheimer's Disease Research Unit at McGill University in Canada, Drug Development for Alzheimer's Disease, Drug Discovery Programmes, Drug Identification, Drug Trials, Drug Trials Failure Rate, Drug-Development Pipeline, Drugs for Treatment of Alzheimer’s Disease, Global Dementia Research, Leuco-methylthioninium-bis (hydromethanesulfonate) (LMTM), Leucomethylthioninium Salts (LMTX), LMTM Monotherapy, LMTX, Ltd., Neurodegeneration, Neurodegenerative Disease Research, Research and Development, Research and Innovation, Research Commitment, Tau, Tau Aggregation, Tau Aggregation Inhibitor Therapy, Tau Aggregation Inhibitors, Tau Pathology, Tau Tangles, Tau-Targeting Drugs, Tauopathy, TauRX, TauRx Therapeutics, Treatment and Prevention of Dementia
|
Leave a comment
Further Funding for the Dementia Research Institute (Gov UK / MRC / Alzheimer’s Society / ARUK)
Summary Additional partnership funding has been announced for Dementia Research Institute (DRI). The Alzheimer’s Society and Alzheimer’s Research UK have each committed £50 million towards supporting the work of the Institute, making the total commitment to date around £250 million … Continue reading →
Posted in Alzheimer's Society, Alzheimer’s Research UK, Charitable Bodies, Commissioning, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, Mental Health, Models of Dementia Care, National, Non-Pharmacological Treatments, Pharmacological Treatments, Quick Insights, UK, Universal Interest
|
Tagged Alzheimer’s Research UK (ARUK), Alzheimer’s Research UK’s Drug Discovery Alliance, ARUK: Alzheimer’s Research UK, Challenge on Dementia (David Cameron), Challenge on Dementia 2020, Cross-Sector Partnerships, David Cameron, Dementia Research, Dementia Research Careers, Dementia Research Funding, Dementia Research Institute (DRI), Dementia Research: UK Impact, Dementia Risk Reduction, Department for Business Innovation and Skills, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Drug Discovery Alliance, Drug Discovery Programmes, Global Action Against Dementia, Global Context, Global Dementia Discovery Fund (2015), Global Dementia Research, Global Leadership, Global Outlook, Hilary Evans: Chief Executive of Alzheimer’s Research UK, International Dementia Research, Jeremy Hughes CBE: Chief Executive of the Alzheimer’s Society, Jo Johnson MP, Jo Johnson: Universities and Science Minister, Living Well with Dementia Research, Medical Research Council (MRC), Medical Research Council (UK), MRC: Medical Research Council, Neurodegeneration, Neurodegenerative Disease Research, Partnership and Collaboration, Partnership Working, Prime Minister’s Challenge On Dementia 2020, Promisary Science, Public Health Strategies, Research and Development, Research and Innovation, Research Commitment, Research Funding, Sir John Savill: Chief Executive of the Medical Research Council, UK Dementia Research Institute
|
Leave a comment
Repurposing of Existing Drugs to Prevent Dementia? (BBC News / Science Advances /Alzheimer’s Research UK)
Summary A number of drugs, already approved as safe for the treatment of other conditions, and which could help protect against Alzheimer’s Disease, are said to have been detected and short-listed for further investigation. Full Text Link Reference Alzheimer’s preventative … Continue reading →
Posted in Alzheimer's Society, Alzheimer’s Research UK, Animal Studies, BBC News, Charitable Bodies, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, NHS Digital (Previously NHS Choices), Pharmacological Treatments, Quick Insights, UK, Universal Interest
|
Tagged Ab42 Fibril Formation, Alzheimer's Research UK, Alzheimer’s Research UK (ARUK), Alzheimer’s Research UK Drug Discovery Institute, Amyloid Beta Protein, Amyloid Cascade Hypothesis, Amyloid Hypothesis, Amyloid Proteins, Amyloid-β (Aβ), Amyloid-β Protein, Anti-Amyloid Therapies, ARUK: Alzheimer’s Research UK, ß-amyloid, BBC Health News, Behind the Headlines, Beta-Amyloid, Bexarotene (Elevated Triglycerides), Bexarotene (Targretin), Center for Molecular Protein Science: Lund University, Cleveland Clinic Lou Ruvo Center for Brain Health, Collaborative Drug Discovery Programmes, Conversion to Dementia From Prodromal Disease, Critical Appraisals, Department of Biochemistry and Structural Biology: Lund University, Department of Chemistry: University of Cambridge, Department of Psychology: University of Nevada, Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Drug Discovery Programmes, European Research Institute for the Biology of Aging (Groningen), Fibrillar Deposits (Alzheimer's Disease), Fibrils, β-Amyloid 1-42 (Aβ42), Lund University (Sweden), Microscopic Worms, Netherlands, Neurofibrillary Tangles (NFTs), Neurological Research, Neurostatin (Hypothetical Construct), Off-Label Drug Repurposing Trials, Off-Licence Drugs, Potential Repurposing of Drugs to Slow Progression of Alzheimer’s Disease, Prodromal Alzheimer's Disease, Protein Aggregation, Repurposing of Drugs, RXR Agonists, Science Advances (Journal), Statins for the Brain (Hypothetical Construct), Sweden, University Medical Centre Groningen, University of Cambridge, University of Groningen, University of Nevada, USA, Worms: C. elegans
|
Leave a comment
European Medicines Agency Consultation on Pharmacological Treatments for Dementia (EMA)
Summary The European Medicines Agency (EMA) has released an updated draft guideline on medicines for the treatment of Alzheimer’s Disease and other types of dementia, for consultative feedback. Full Text Link Reference Consultation on revised guideline on medicines to treat … Continue reading →
Posted in Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Management of Condition, Mental Health, Models of Dementia Care, Pharmacological Treatments, Quick Insights, Standards
|
Tagged Accelerating Alzheimer's Research and Drug Development, Alzheimer’s Disease Biomarkers, Behavioural and Psychiatric Symptoms of Dementia, Behavioural and Psychological Symptoms of Dementia (BPSD), Biomarker Assessments in Alzheimer’s Disease, Biomarker Assessments in Alzheimer’s Disease Clinical Trials, Biomarker Assessments in Clinical Trials, Biomarker Development, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Blood Proteins as Biomarkers of Disease Research, Blood-Based Biomarkers of Pre-Symptomatic Alzheimer’s Disease, BPSD: Behavioral and Psychological Symptoms of Dementia, Cardiovascular Adverse Events, Clinical Diagnostic Criteria, Committee for Medicinal Products for Human Use (CHMP), Comparison IWG and NIA-AA Criteria for Clinical Diagnosis of Alzheimer´s Disease, Diagnostic Tests, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Drug Development for Alzheimer's Disease, Drug Discovery Programmes, Drug Identification, Drug Target Validation, Drug-Development Pipeline, Drugs for Treatment of Alzheimer’s Disease, Early Detection of Preclinical Disease, Early Diagnosis, Early Diagnosis of Alzheimer's Disease, Early Diagnostic Criteria, EMA Central Nervous System Working Party, EMA: European Medicines Agency, Enrichment of Study Populations, European Medicines Agency, European Medicines Agency (EMA), Genetic Testing, Genetic Triggers, Genetics of Alzheimer's Disease, Guideline on Clinical Investigation of Medicines for Alzheimer’s Disease and Other Dementias, Guideline on Medicinal Products for the Treatment of Alzheimer’s Disease and Nine Other Dementias, International Organisations, International Programmes, International Working Group (IWG), Long-Term Efficacy and Safety Studies, Medical Research, Medicines Development, Medicines Mechanism of Action, National Institutes of Health (NIH), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurological Adverse Events, Neurological Disorders, Novel Targets in Neurodegeneration, Ordering of Alzheimer's Disease Biomarkers, Pharmaceutical Industry, Pharmacological Research, Preclinical Alzheimer's Disease, Preclinical Biomarkers in Alzheimer's Disease, Preclinical Indicators and Dementia, Preclinical Indicators in Alzheimer's Disease, Prodromal Alzheimer's Disease, Psychiatric Adverse Events, Research and Development, Research and Innovation, Research Commitment, Research Consortia, Research Culture, Research Networks, Research Programmes, Safety and Efficacy Markers, Stratification of Subgroups (Clinical Trials), Target Discovery and Preclinical Validation, Therapeutic Target(s): Identification, Timely Diagnosis
|
Leave a comment
CoEN “Pathfinder” Funding for Neurodegenerative Disease Research Announced (MRC)
Summary The Centres of Excellence in Neurodegenerative Disease (CoEN) initiative has awarded £3.6 million to 11 international “Pathfinder” innovation projects. These projects aim to identify and validate new potential drugs and develop innovative therapeutic approaches for the dementia, and other conditions such … Continue reading →
Posted in Commissioning, For Researchers (mostly), In the News, International, Models of Dementia Care, Parkinson's Disease, Pharmacological Treatments, UK, Universal Interest
|
Tagged Agence Nationale de la Recherche (ANR), Amyloidogenic and Inflammatory Pathways, B-Cell Activating Factor (BAFF)/A Proliferation-Inducing Ligand (APRIL) System, BAFF/APRIL, Belgium, C9orf72: Genetic Cause of Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, Canada, Canadian Institutes of Health Research, Canadian Institutes of Health Research (CHIR), Centres of Excellence in Neurodegenerative Disease (CoEN), Centres of Excellence in Neurodegenerative disease (CoEN) Pathfinder Grants, CoEN Funding Partners, Dementia Research, Dementia Research Funding, Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) Bonn, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Drug Discovery Programmes, France, French Agence Nationale de la Recherche, Genome-Wide Association Studies (GWAS), Germany, Global Action Against Dementia, Global Context, Global Leadership, Human iPSCs, Impaired Lysosomal Flux in Alzheimer’s Disease, Induced Pluripotent Stem Cells (iPSCs), Instituto de Salud Carlos III (ISCIII), International Dementia Research, iPSCs, Ireland, Italian Ministry of Health, Italy, Medical Research Council (MRC), Medical Research Council (UK), microRNA, MicroRNAs, Mitochondria, Mitochondrial Dysfunction, Mitochondrial Neurodegeneration, MRC: Medical Research Council, MT5-MMP, Mutant C9Orf72 ALS/FTD, Neurodegeneration, Neurodegenerative Disease Research, Pathfinder” Innovative Research Projects, Presymptomatic White Matter Changes in Huntington Disease, Rab GTPases, Research and Development, Research and Innovation, Research Commitment, Research Funding, Science Foundation Ireland (SFI), Slovak Ministry of Education Science Research and Sport, Slovakia, Spain, Super-Resolution STED Microscopy, Synuclein Toxicity, Synucleinopathy, Synucleinopathy Progression, Unifying Theory of Parkinson’s Disease, Vlaams Instituut voor Biotechnologie, Worms: C. elegans
|
Leave a comment
